Inhibrx Biosciences Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
(a) Exhibits.
| Exhibit No. | Description of Exhibit | Filed Herewith | Form | Incorporated By Reference File No. | Date Filed |
|---|---|---|---|---|---|
| 2.1^ | Agreement and Plan of Merger, dated January 22, 2024, by and among Inhibrx, Inc., Aventis, Inc. and Art Acquisition Sub, Inc. | 8-K | 001-39452 | 1/23/2024 | |
| 2.2^ | Separation and Distribution Agreement, dated January 22, 2024, by and among Inhibrx, Inc., Ibex SpinCo, Inc. and Aventis Inc. | 8-K | 001-39452 | 1/23/2024 | |
| 3.1 | Amended & Restated Certificate of Incorporation of Inhibrx Biosciences, Inc. | 8-K | 001-42031 | 5/30/2024 | |
| 3.2 | Amended & Restated Bylaws of Inhibrx Biosciences, Inc. | 8-K | 001-42031 | 5/30/2024 | |
| 4.1 | Form of Warrant to Purchase Stock. | 10 | 001-42031 | 4/25/2024 | |
| 10.1^ | Transition Services Agreement, dated as of May 29, 2024, by and between Inhibrx Biosciences, Inc. and Inhibrx, Inc. | 8-K | 001-42031 | 5/30/2024 | |
| 10.2 | Form of Indemnification Agreement. | 10 | 001-42031 | 4/25/2024 | |
| 10.3^ | Registration Rights Agreement, dated as of May 29, 2024, by and among Inhibrx Biosciences, Inc. and the parties thereto. | 8-K | 001-42031 | 5/30/2024 | |
| 10.4+ | Executive Employment Agreement, effective as of May 30, 2024, by and between Inhibrx Biosciences, Inc. and Mark Lappe. | S-1 | 333-280127 | 6/11/2024 | |
| 10.5+ | Executive Employment Agreement, effective as of May 30, 2024, by and between Inhibrx Biosciences, Inc. and Brendan Eckelman, Ph.D. | S-1 | 333-280127 | 6/11/2024 | |
| 10.6+ | Executive Employment Agreement, effective as of May 30, 2024, by and between Inhibrx Biosciences, Inc. and Kelly Deck. | S-1 | 333-280127 | 6/11/2024 | |
| 10.7+ | 2024 Omnibus Incentive Plan. | S-8 | 333-279840 | 5/30/2024 | |
| 10.8+ | Form of Stock Option Grant Notice under the 2024 Omnibus Incentive Plan. | 8-K | 001-42031 | 5/30/2024 | |
| 10.9+ | Form of Restricted Stock Unit Agreement under the 2024 Omnibus Incentive Plan. | S-8 | 333-279840 | 5/30/2024 | |
| 10.10† | License Agreement, dated December 20, 2018, by and between Inhibrx, Inc. and bluebird bio, Inc. | S-1 | 333-231907 | 6/3/2019 | |
| 10.11† | Option and License Agreement, dated June 9, 2020, by and between Inhibrx, Inc. and bluebird bio, Inc. | S-1 | 333-240135 | 7/28/2020 | |
| 10.12† | License Agreement, dated July 1, 2013, by and between INBRX 103, LLC and Celgene Corporation. | S-1 | 333-231907 | 6/3/2019 | |
| 10.13 | Amendment to License Agreement, dated November 23, 2018, by and among Inhibrx, Inc., INBRX 103, LLC and Celgene Corporation. | S-1 | 333-231907 | 6/3/2019 | |
| 10.14+ | Nonemployee Director Compensation Policy. | X | |||
| 31.1 | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X |
| 32.1* | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X |
| 32.2* | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document | X |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document contained in Exhibit 101 | X |
^ Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally to the SEC a copy of any omitted exhibits or schedules upon request. Pursuant to Item 601(a)(6) of Regulation S-K, certain information from this exhibit have been redacted as their disclosure would constitute a clearly unwarranted invasion of personal privacy.
† Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.
- This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
- Management compensation plan or arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.